Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use PREVYMIS safely and effectively. See full prescribing information for PREVYMIS. PREVYMIS® (letermovir) tablets, for oral use PREVYMIS® (letermovir) oral pellets PREVYMIS® (letermovir) injection, for intravenous use Initial U.S. Approval: 2017
Medication labelWhy this: Advisory · dailymed-prescription
PREVYMIS® is indicated for prophylaxis of cytomegalovirus (CMV) infection and disease in adult and pediatric patients 6 months of age and older and weighing at least 6 kg who are CMV-seropositive recipients [R+] of an allogeneic hematopoietic stem cell transplant (HSCT). PREVYMIS is indicated for prophylaxis of CMV disease in adult and pediatric patients 12 years of age and older and weighing at least 40 kg who are kidney transplant recipients at high risk (Donor CMV seropositive/Recipient CMV seronegative [D+/R-]).
- generic_name
- letermovir
- product_names
- LETERMOVIR
- ndc
- 0006-3075, 0006-3075-01, 0006-3075-02, 0006-3075-03, 0006-3075-04, 0006-3076, 0006-3076-01, 0006-3076-02, 0006-3076-03, 0006-3076-04, 0006-5003, 0006-5003-02, 0006-5003-01, 0006-5004, 0006-5004-02, 0006-5004-01, 0006-5086, 0006-5086-01, 0006-5085, 0006-5085-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en